P.A.D. Coalition - Saving Limbs and Lives...

Resources: Clinical Trials


Clinical Trials

 

Clinical Research to Improve Blood Flow in Legs

 

 

DEFINITIVE™ Ca++ Study – www.legpaintrial.com

Study to evaluate the use of the SilverHawk™ Plaque Excision System and the SpiderFX Embolic Protection Device in the endovascular treatment of moderate to severely calcified femoropopliteal artery lesions.

DEFINITIVE™ LE Study

A study designed confirm the value of plaque excision with the SilverHawk™ System.

Clinical Research Study for Patients with Intermittent Claudication

 

Study of the investigational drug trans sodium crocetinate (TSC) in patients with Peripheral Arterial Disease (PAD) and leg pain with walking (intermittent claudication).

Critical Limb Ischemia Research Study

Study on the use of using stem cells for Critical Limb Ischemia.

 

CLEVER Study


Claudication: Exercise Versus Endoluminal Revascularization (CLEVER): The National Heart, Lung, and Blood Institute (NHLBI) is sponsoring a trial for patients with cardiovascular diseases, peripheral vascular diseases, or atherosclerosis to compare the effectiveness of aortic stent surgery versus exercise therapy.

 

Emory University School of Medicine

Do you have peripheral arterial disease? Do your legs ache when you walk due to arterial blockages? Emory University is conducting a study funded by the National Institutes of Health (NIH) to examine whether a drug can improve circulation in legs with arterial blockages by stimulating growth of new blood vessels. Suitable subjects will be required to undergo exercise testing and other tests over a six-month study period and will be compensated for their participation. For more information, click here, or call 404-712-7847.

 

 

To learn about more clinical trials, please visit the Vascular Disease Foundation's Clinical Trials Resource Center:  www.vdf.org/clinical

This information is included for patient information only. The Vascular Disease Foundation does not endorse any clinical research studies.